文献速递银屑病与炎症性皮肤病

依那西普临床试验中因疗效不足退出患者的时点与PASI、DLQI分析

Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials.
PubMed 文献 · Br J Dermatol · 2018-01-02

该研究汇总10项依那西普治疗银屑病临床试验的6119例患者数据,分析因疗效不足退出者的时间分布及PASI、DLQI特征。结果显示退出高峰出现在第75至85天(累积百分比从46%升至73%),第80天左右为关键时点,退出者中达到PASI 75者罕见,多数改善轻微、病情稳定或恶化。

要点

  • 因疗效不足退出高峰在第75至85天,累积退出比例从46%升至73%。
  • 第80天左右为患者可能失去等待意愿的关键时点。
  • 退出者中达到PASI 75者罕见,多数改善轻微或病情稳定/恶化。

核心结论

  • 依那西普治疗银屑病临床试验中,因疗效不足退出的关键时点约在第80天,退出者多数PASI改善有限。

研究设计与样本

  • 汇总10项依那西普治疗银屑病临床试验的6119例患者数据,分析因疗效不足退出者与继续试验者的PASI和DLQI。

主要发现

  • 6119例患者中128例因疗效不足或同义原因退出。
  • 退出患者累积百分比在第75至85天从46%升至73%。
  • 退出者中达到≥PASI 75者罕见。
  • 多数退出患者表现为改善轻微、病情稳定或恶化。

关键数值与推荐

  • PASI 75定义为较基线PASI至少改善75%。
  • 退出高峰第75至85天累积百分比从46%升至73%。

临床怎么用

  • 对依那西普治疗银屑病患者,第80天左右应评估疗效与患者等待意愿。
  • 若至第80天左右PASI改善有限,需考虑调整治疗或沟通预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patient-reported outcomes in psoriasis studies are assessed at specific study time points. If a treatment has not become effective by a certain time point, it may increase the likelihood of patients being dissatisfied and leaving a clinical study. OBJECTIVES: To generate evidence concerning the number of patients dropping out of etanercept trials over time including Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) data. METHODS: Data from patients with psoriasis in 10 trials with etanercept were pooled. Analyses were performed for (i) patients who dropped out because of 'lack of efficacy' and (ii) patients who continued the trial. The PASI and DLQI data were summarized for different time points. The distribution of dropout over time, PASI, DLQI and the proportion of patients dropping out with given treatment responses were calculated. RESULTS: Of 6119 patients, 128 dropped out because of lack of efficacy (or synonym). The highest increase of patients dropping out happened between day 75 and 85 (cumulative percentage rise from 46% to 73%). The lowest PASI of patients dropping out was 6·3 within 120 days. Individuals who dropped out who achieved ≥ PASI 75 (at least a 75% improvement from baseline PASI) were rare. CONCLUSIONS: A critical time when many patients might have lost their willingness to wait for their treatment with etanercept to show a better effect appeared to be at around day 80. Most of the patients dropping out showed little improvement, stable disease or worsening of their psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Nast A, Dilleen M, Liyanage W, et al. Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials. Br J Dermatol. 2018. PMID: 28771657. doi:10.1111/bjd.15864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。